drugset / Trial / NCT00313014

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

NCT00313014

Phase 3 Terminated 660 enrolled Purdue Pharma LP
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) 20 in comparison to the buprenorphine transdermal system (BTDS) 5 and oxycodone immediate-release in subjects with moderate to severe low back pain currently treated with oral opioids. The double-blind treatment intervention duration is 12 weeks during which time supplemental analgesic medication (acetaminophen, ibuprofen) will be provided to all subjects in addition to study drug.

Timeline

Start
2004-02
Primary completion
2005-09
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 5 ug Other
Subject Buprenorphine Other / unclassified 20 ug Other
Subject Oxycodone Other / unclassified 40 mg Oral

Indications

No indication recorded.